Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Optimizing Treatment of Advanced Pancreatic Cancer

February 11th 2014

Cost Effectiveness of Therapies in Pancreatic Cancer

February 11th 2014

Gemcitabine/Nab-Paclitaxel in Advanced Pancreatic Cancer

February 11th 2014

Introduction: FOLFIRINOX in Metastatic Pancreatic Cancer

February 11th 2014

Hopes Revived for Targeting the "Undruggable" RAS Family

February 11th 2014

The members of the RAS oncogene family are central cogs in many different cell-signaling pathways, coordinate a variety of important cellular processes, and are highly mutated in a number of different cancers, including several with extremely poor prognosis.

Final Thoughts on Improving Outcomes in NSCLC

February 7th 2014

Skeletal-Related Event Management in Lung Cancer

February 7th 2014

Next-Generation Sequencing in Lung Cancer

February 7th 2014

Determining When to Administer Maintenance Therapy in NSCLC

February 7th 2014

Maintenance Therapy in Non-Small Cell Lung Cancer

February 7th 2014

Optimizing Maintenance Therapy in NSCLC

February 7th 2014

Adjuvant EGFR Inhibition in Patients With NSCLC

February 7th 2014

Next-Generation Targeted Therapies in NSCLC

February 7th 2014

Development of ALK Inhibitors in Advanced NSCLC

February 7th 2014

Second-Generation ALK Inhibitors in NSCLC

February 7th 2014

Current Status of Immunotherapy in NSCLC

February 7th 2014

Immune Checkpoint Inhibitor Combinations in NSCLC

February 7th 2014

Checkpoint Inhibitor Related Pseudoprogression in NSCLC

February 7th 2014

Introduction: Checkpoint Inhibition in NSCLC

February 7th 2014

Dr. Peeters on KRAS/NRAS Mutations in mCRC

February 6th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of mCRC